Philips CPAP Recall: What Happened, What's Next, and Your Alternatives in 2026

In June 2021, Philips Respironics issued one of the largest medical device recalls in history, pulling millions of CPAP, BiPAP, and mechanical ventilator devices from the market. The reason: a polyester-based polyurethane (PE-PUR) sound abatement foam inside the machines was degrading, potentially releasing toxic particles and gases directly into the pressurized air that patients breathed every night. Five years later, the fallout continues. Lawsuits are still being settled, affected patients are still seeking answers, and trust in CPAP therapy has been fundamentally shaken. If you are one of the millions affected — or simply someone who has been hesitant to start CPAP because of the recall — here is what you need to know in 2026.

The Full Timeline: How the Recall Unfolded

The problems did not begin in 2021. Philips had received complaints about black particles and debris appearing in their devices as early as 2015, according to FDA records. Internal testing documents later revealed that the company was aware of potential foam degradation risks but continued manufacturing and selling devices with the same PE-PUR foam for years.

On June 14, 2021, Philips issued a voluntary recall notification covering an estimated 3.5 to 4 million devices sold in the United States alone, with millions more affected globally. The recall encompassed the DreamStation first-generation CPAP and BiPAP machines, the SystemOne series, and several ventilator models. Patients were told to stop using their devices immediately unless no alternative was available and discontinuation posed greater health risk than continued use — a cruel paradox for people with severe sleep apnea who depended on their machines to breathe safely at night.

The FDA classified the recall as Class I, its most serious category, indicating a reasonable probability that the defective devices could cause serious injury or death. The agency issued multiple safety communications and later escalated enforcement actions against Philips, including consent decrees that restricted the company's ability to manufacture and distribute sleep and respiratory care products in the United States.

Philips initially offered a repair-and-replace program, substituting the degrading PE-PUR foam with a silicone-based alternative. But the replacement process moved slowly, with many patients waiting months or over a year to receive repaired devices. Independent testing of the replacement foam also raised questions about whether the new material fully addressed all safety concerns, leading to further FDA scrutiny.

Health Risks: What the Foam Exposure May Have Caused

The PE-PUR foam could degrade in several ways. Heat and humidity — both present inside an operating CPAP machine — accelerated the breakdown. Certain cleaning methods, particularly ozone-based sanitizers, further degraded the foam. When it broke down, the foam released visible black particles and invisible chemical off-gases, including formaldehyde, toluene, and other volatile organic compounds.

Patients breathed these contaminants through their masks for hours each night, sometimes for years before the recall was announced. Reported health complaints include headaches, upper airway irritation, coughing, sinus infections, chest pressure, and nausea. More serious concerns include potential links to respiratory inflammation, organ damage, and cancer, though establishing direct causation from the foam exposure remains an area of ongoing medical and legal investigation.

As Reuters has extensively reported, the scope of potential harm is enormous simply because of the number of people exposed. Millions of patients used the affected devices nightly, often for years, creating prolonged and repeated inhalation exposure to degraded foam products. The long latency period for some potential health effects, particularly cancer, means the full clinical impact may not be understood for years to come.

Lawsuit Status and Settlements in 2026

The legal response to the recall has been massive. Thousands of individual lawsuits and class action claims were consolidated into multidistrict litigation (MDL) in the Western District of Pennsylvania. As of early 2026, Philips has agreed to settlements exceeding $1.1 billion to resolve claims related to the economic loss class — people who purchased or rented the recalled devices and suffered financial harm from their loss of use.

Personal injury claims — from patients alleging that foam exposure caused specific health conditions — are proceeding on a separate track. These cases involve more complex medical evidence linking individual health outcomes to the device exposure, and many are still in discovery or early trial phases. Legal experts expect the personal injury litigation to continue through 2027 and potentially beyond, with eventual settlements or verdicts that could significantly exceed the economic loss figures.

For affected patients, the practical takeaway is this: if you owned or used a recalled Philips device, you may be eligible for compensation. Consult with an attorney experienced in medical device litigation to understand your options, and preserve any records of your device purchase, usage, and any health issues that developed during or after use.

The Trust Crisis: Why Millions Abandoned CPAP

Beyond the direct health risks and financial losses, the recall inflicted lasting damage on patient trust in CPAP therapy as a whole. Surveys conducted since 2021 consistently show that a significant percentage of sleep apnea patients either abandoned CPAP entirely after the recall or became reluctant to start it. For a therapy that already struggled with notoriously low long-term compliance rates — studies show that 30 to 50 percent of CPAP users abandon the therapy within the first year even without a recall — the Philips debacle compounded an existing adherence problem.

This trust crisis has real health consequences. Untreated obstructive sleep apnea is associated with increased risk of hypertension, heart attack, stroke, type 2 diabetes, and cognitive decline. Patients who stopped using their CPAP because of the recall and did not transition to an alternative therapy are living with the cumulative damage of untreated airway obstruction every night. Understanding the differences between CPAP and mouthpiece therapy helps patients see that abandoning one device does not mean living without treatment.

Your Alternatives in 2026

If you were affected by the recall, or if the recall has made you wary of starting CPAP, there are several alternative treatment paths worth considering. The American Academy of Sleep Medicine recognizes multiple therapies for obstructive sleep apnea and snoring, and the choice depends on the severity of your condition.

New-generation CPAP devices from other manufacturers. ResMed, Fisher & Paykel, and other manufacturers were not affected by the Philips recall. Their devices use different foam materials and construction methods. If CPAP is the right therapy for your severity level, switching to a non-recalled device from a different manufacturer is a straightforward option. Prices range from $500 to $1,500 for the device, plus ongoing supply costs.

Custom oral appliances from dental sleep medicine specialists. For mild-to-moderate OSA and for primary snoring, mandibular advancement devices fitted by a dentist trained in dental sleep medicine are an established alternative. These CPAP alternatives work by repositioning the lower jaw forward, opening the airway mechanically without pressurized air, motors, foam, or electricity. Custom devices typically cost $1,500 to $3,000 and require periodic dental visits for adjustment. The compliance rates for oral appliances are significantly higher than for CPAP, because the devices are simpler, quieter, and easier to travel with.

Over-the-counter anti-snoring mouthpieces. For snorers without diagnosed severe OSA, an OTC mouthpiece offers the same mandibular advancement mechanism as a custom device at a fraction of the cost. Snorple, at $69, combines mandibular advancement with tongue stabilization in a single device — no prescription, no dental appointments, no foam, no electricity, and no recall risk. It is the simplest and most affordable physical intervention for snoring available today. If you are considering switching from CPAP to an oral appliance, this is a practical starting point.

Positional therapy. For patients whose OSA is primarily positional — meaning it occurs mostly when sleeping on the back — positional therapy devices that encourage side sleeping can reduce apnea events without any airway device. This approach works best as a complement to other treatments rather than a standalone solution for most patients.

Surgical options. For severe OSA that does not respond to CPAP or oral appliances, surgical interventions including uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (Inspire implant) are available. These are more invasive and typically reserved for cases where conservative treatments have failed.

Emerging pharmacological treatments. New medications under investigation, including AD109 and sulthiame, are showing promise for treating OSA by increasing upper airway muscle tone during sleep. While not yet widely available, these sleep apnea pills represent a potential future option for patients who cannot tolerate device-based therapy.

What to Do If You Were Affected

If you used a recalled Philips device, here are the practical steps to take right now.

Register your device with the Philips recall portal if you have not already done so. Even if you have already received a replacement, registration establishes your record as an affected patient for potential future claims.

Consult your physician. Discuss your exposure history and any symptoms that may have developed during your period of device use. Your doctor can order appropriate testing or monitoring and document any health concerns in your medical record.

Do not go untreated. This is the most important point. The recall created a situation where many patients chose the risk of untreated sleep apnea over the perceived risk of their device. That is an understandable but dangerous trade-off. Untreated severe OSA carries documented risks of cardiovascular events, metabolic disease, and cognitive impairment. Transition to an alternative therapy — whether that is a non-recalled CPAP, an oral appliance, or an OTC mouthpiece — rather than simply stopping treatment. Review our guide to FDA-cleared snoring devices for options that meet regulatory standards.

Explore legal options. If you experienced health problems during or after using a recalled device, consult with an attorney who specializes in medical device litigation. Many firms offer free initial consultations and work on contingency, meaning you pay nothing unless you receive compensation.

Lessons for the Sleep Device Industry

The Philips CPAP recall is a cautionary tale about what happens when a manufacturer prioritizes cost and convenience over material safety, and when regulatory oversight fails to catch a known problem early enough. It has accelerated interest in simpler, lower-risk sleep devices that do not involve pressurized air, foam components, or complex electronics.

Oral appliances — both custom and over-the-counter — have benefited from this shift precisely because they are mechanically simple. A well-designed mouthpiece has no foam to degrade, no motor to fail, no electricity to conduct, and no pressurized air pathway to contaminate. The mechanism is entirely mechanical: reposition the jaw, open the airway, reduce obstruction. The simplicity is the safety feature. Our complete guide to stopping snoring covers the full range of available approaches.

For patients evaluating any sleep device in 2026, the Philips experience offers a clear lesson: ask what materials are in the device, understand how those materials interact with heat, humidity, and cleaning agents, verify the manufacturer's track record with regulatory agencies, and have a backup plan in case your primary therapy is ever disrupted.